Valeant Pharmaceuticals International, Inc. (VRX) Stock Rating Reaffirmed by Barclays PLC

Valeant Pharmaceuticals International, Inc. (VRX) Stock Rating Reaffirmed by Barclays PLC


's stock had its "hold" rating restated by Barclays PLC in a note issued to investors on Thursday. They currently have a $34.00 price objective on the specialty pharmaceutical company's stock.



from Biotech News